DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20172302

Prevalence of overactive bladder symptoms and urinary incontinence in a tertiary care hospital in Egypt

Mustafa Bahloul, Ahmed M. Abbas, Mervat A. Abo-Elhagag, Elwani Elsnosy, Alaa-eldein A. Youssef

Abstract


Background: The current study aims to estimate the prevalence of Overactive bladder (OAB) and urinary incontinence (UI) among women attending Assiut Woman's Health Hospital. Additionally, to explore the impact of UI and OAB on The Quality of Life (QOL) of women.

Methods: A population-based survey included participants aged 18 years and older selected from Assiut Woman's Health Hospital and received The Bristol Female Lower Urinary Tract Symptoms Questionnaire (BFLUTSQ). OAB was defined in to two versions using the international continence society (ICS) definition of 2002 as either urgency sometimes or more alone (OAB1) or urgency sometimes or more with frequency more than eight times per day and /or nocturia once or more per night (OAB2). Incontinence and other LUTS were positive if answer scores ≥2 to BFLUTSQ question for incontinence and other LUTS.

Results: The total prevalence of OAB was 39.0% (351 women). The prevalence of OAB dry and OAB wet was 26% (234 women) and 13% (117 women), respectively, which suggested that 66.7% suffer from OAB dry and 33.3% suffer from OAB wet. The prevalence of dry OAB is significantly higher than wet OAB. The overall prevalence of UI was 22.2% (201 women). The prevalence of stress UI, urge UI and mixed UI was 5.7%, 5.1% and 11.4%, respectively.

Conclusions: OAB symptoms and UI are highly prevalent. Furthermore, both of them have severe effects on daily and sexual life as well as being related to psychological symptoms such as anxiety and depression.


Keywords


Lower urinary tract, Overactive bladder, Stress incontinence, Urinary incontinence

Full Text:

PDF

References


Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. NeurourolUrodyn. 2002, 21: 167–178.

Steers WD, Barrett DM, WeinAJ. Voiding Dysfunction: Diagnosis, Classification, and Management. In Jay Y. Gillenwater, John T. Grayhack, et al (eds):Adult and Pediatric Urology, vol.3. Anne S. Patterson, 1996 ; 26B ; 1220- 1310.

Ouslander JG. Management of Overactive Bladder. N Engl J Med. 2004;350(8):786-99.

Milson I, Abrams P, Cardozo L, RobertsRG, Thuroff J,Wein AG.How wide spead are symptoms of an overactive bladder and how managed? A population-based prevalence study. BJU Int. 2001;87:760-6.

Coyne K ,Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, et al. Psychometric validation of overactive bladder symptom and health-related quality of life questionnaire: the OAB- q.Qual life Res. 2002; 11; 563- 74.

Abrams P, Cardozo L, Fall M, et al: The standardization of terminology in lower urinary tract function: Report from the standardization sub-committee of the International Continence Society. Urology. 2003; 61:37-49.

Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010; 29: 4.

Fitzgerald MP, Brubaker L. Variability of 24-hour voiding diary variables among asymptomatic women. J Urol. 2003; 169: 207.

Tikkinen KA, Johnson TM, Tammela TL, et al. Nocturia frequency, bother and quality of life: how often is too often? A population-based study in Finland. Eur Urol. 2010; 57:488.

Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinaryurgency and frequency on health-related quality of life in overactivebladder: Results from a national community survey. Value Health. 2004; 7:455-463.

Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of Overactive Bladder in united states. World Urol. 2004;20:327-36.

Kelleher CJ, Resse PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodin for overactive bladder. Am J Manag Care. 2002; 8 (Suppl 19):S608-S615.

Domchowski RR, Newman DK. Impact of Overactive Bladder on Women In the United States: results of a national survey. Curr Med Res Opin. 2007;23(1):65 -76.

El-Azab AS, MoeenAM, et al. The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinum toxin A and augmentation cystoplasty. Arab J Urol. 2013;11:4.

Altaweel W, Alharbim M. Urinary incontinence. Prevalence, risk factors, and impact on health related quality of life in Saudi women. Neurourol Urodyn. 2012; 13: 642-5.

Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well- being in six European Countries. BJU Int.2006;97:96-100.

Lapitan MC, Chye PL. Asia – Pacific Continence Advisory Board. The epidemiology of overactive bladder among females in Asia: a questionnaire survey- Int Urogynecol JP Pelvic Floor Dysfunct. 2001;12:229-31.

Zhang W, Song Y, He X, et al. Prevalence and risk factors of overactive bladder symptoms in Fuzhou Chinese women . Neurourol Urodyn. 2006;25:717-21.

Botlero F, Urquhart DM, Davis SR, Bell RJ. Prevalence and incidence of UI in women review of the literature and investigation of methodological issues. Int Urol. 2008;15:230-4.

Lasserre A , Pelat C, Gueroult V, Hanslik T, Chartier–Kastler E, Blancho T, et al. UI in French women: prevalence, risk factors, and impact on quality of life. Eur Urol. 2009; 56:177-83.

Correia S, Dinis P, Rolo F, Lunet N. Prevalence, treatment and know risk factors of urinary incontinence and overactive bladder in the non institutionalized Portugues population.IntUrogynecol JP Pelvic Floor Dysfunct. 2009;20:1481-9.

Cerruto MA, D' Elia C, Aloisi A, Fabrello M, Artibani W. Prevalence, incidence and obstetric factors ' impact on female urinary incontinence in Europe: a systemic review Urol Int. 2013;90:1-9.

El-Azab AS, Mohammed EM, Sabra HI. The prevalence and risk factors of urinary incontinence and its influence on the quality of life among Egyptian women.Neurourolurodyn. 2007;26:783-8.

Peyrat L, Haillot O, Bruyere F, Boutin JM, Bertrand P, Lanson Y. Prevalence and risk factors of urinary incontinencein young and middle aged women. BJU Int. 2002;89:61- 6.

kinchen KS, Burgio K, Diokno AC, Fultz NH, Bump R, Obenchain R. Factor associated women's decisions to seek treatment for urinary incontinence. J Women Health (larchmt) 2003;12:687-98.

AL-Badr A, Brasha H, Al- Raddadi R, Noorwali F, Ross S. Prevalenceof urinary incontinence among Saudiwomen.Int J Gynaecol Obstet. 2012;117:160-3.

Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS). Eur Urol. 2005;47:824-37.

Irwin P, Somov P, Ekwueme K. Patient reported outcomes of abobotulinum toxin A injection treatment for idiopathic detrusor overactivity: Apragmatic approach to management in secondary care. J Clin Urol. 2013;6:1.